受试者n |
383 |
388 |
666 |
671 |
3445 |
3450 |
Age years |
63.9±8.6 |
64.2±8.2 |
65.9±8.2 |
66.2±7.8 |
65.1±7.8 |
65.1±8.0 |
男性 |
330 (86%) |
328(85%) |
607(91%) |
616 (92%) |
2464 (72%) |
2496 (72%) |
Body mass index kg·m−2 |
22.5±3.2 |
22.6±3.4 |
23.1±3.9 |
23.3±4.1 |
28.9±5.7 |
28.9±5.8 |
Baseline post-bronchodilator FEV1L |
1.94±0.54 |
1.93±0.52 |
1.43±0.31 |
1.43±0.30 |
1.75±0.39 |
1.76±0.40 |
Post-bronchodilator FEV1% pred |
78.1±17.1 |
77.9±15.8 |
60.7±6.4 |
60.9±6.3 |
59.5±6.0 |
59.5±6.1 |
Current smokers |
154 (40%) |
160 (41%) |
231 (35%) |
221 (33%) |
1705(49%) |
1647 (48%) |
每年加重率 |
0.38 |
0.20 |
0.54 |
0.33 |
0.31 |
0.23 |
Hospitalised exacerbation rate per year |
0.07 |
0.03 |
0.15 |
0.08 |
0.05 |
0.05 |
Post-bronchodilator rate of decline in FEV1mL per year, mean(se) |
51 (6) |
29(5) |
56(7) |
40 (6) |
44 (3) |
37 (3) |
活动差异versus安慰剂ML每年(95%CI) |
22 (6 to 37) |
16 (−1 to 34) |
7 (−1 to 14) |
Post-bronchodilator rate of decline in FEV1#% pred per year, mean(se) |
2.1 (0.2) |
1.2(0.2) |
2.4 (0.3) |
1.7 (0.3) |
1.5 (0.1) |
1.2(0.1) |
活动差异versusplacebo % pred per year (95% CI) |
0.9 (0.2 to 1.5) |
0.7 (−0.1 to 1.4) |
0.2 (0.0 to 0.5) |